These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19917716)

  • 1. Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection.
    Murhandarwati EE; Wang L; de Silva HD; Ma C; Plebanski M; Black CG; Coppel RL
    Infect Immun; 2010 Feb; 78(2):680-7. PubMed ID: 19917716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
    Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
    Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.
    Yoshida S; Nagumo H; Yokomine T; Araki H; Suzuki A; Matsuoka H
    PLoS One; 2010 Oct; 5(10):e13727. PubMed ID: 21060850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The generation and evaluation of two panels of epitope-matched mouse IgG1, IgG2a, IgG2b and IgG3 antibodies specific for Plasmodium falciparum and Plasmodium yoelii merozoite surface protein 1-19 (MSP1(19)).
    Adame-Gallegos JR; Shi J; McIntosh RS; Pleass RJ
    Exp Parasitol; 2012 Apr; 130(4):384-93. PubMed ID: 22343045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
    Otsyula N; Angov E; Bergmann-Leitner E; Koech M; Khan F; Bennett J; Otieno L; Cummings J; Andagalu B; Tosh D; Waitumbi J; Richie N; Shi M; Miller L; Otieno W; Otieno GA; Ware L; House B; Godeaux O; Dubois MC; Ogutu B; Ballou WR; Soisson L; Diggs C; Cohen J; Polhemus M; Heppner DG; Ockenhouse CF; Spring MD
    Malar J; 2013 Jan; 12():29. PubMed ID: 23342996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region.
    Ahlborg N; Ling IT; Howard W; Holder AA; Riley EM
    Infect Immun; 2002 Feb; 70(2):820-5. PubMed ID: 11796616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malaria parasite-inhibitory antibody epitopes on Plasmodium falciparum merozoite surface protein-1(19) mapped by TROSY NMR.
    Morgan WD; Lock MJ; Frenkiel TA; Grainger M; Holder AA
    Mol Biochem Parasitol; 2004 Nov; 138(1):29-36. PubMed ID: 15500913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys.
    Hui GS; Nikaido C; Hashiro C; Kaslow DC; Collins WE
    Infect Immun; 1996 May; 64(5):1502-9. PubMed ID: 8613353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam.
    Murhandarwati EE; Wang L; Black CG; Nhan DH; Richie TL; Coppel RL
    Infect Immun; 2009 Oct; 77(10):4510-7. PubMed ID: 19620342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production, characterisation and immunogenicity of a plant-made Plasmodium antigen--the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1.
    Ma C; Wang L; Webster DE; Campbell AE; Coppel RL
    Appl Microbiol Biotechnol; 2012 Apr; 94(1):151-61. PubMed ID: 22170105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii.
    Kedzierski L; Black CG; Goschnick MW; Stowers AW; Coppel RL
    Infect Immun; 2002 Dec; 70(12):6606-13. PubMed ID: 12438332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro.
    Egan AF; Burghaus P; Druilhe P; Holder AA; Riley EM
    Parasite Immunol; 1999 Mar; 21(3):133-9. PubMed ID: 10205793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rice-produced MSP142 of Plasmodium falciparum elicits antibodies that inhibit parasite growth in vitro.
    Chen Q; Liang W; Qian F; Qian B; Cao J; Zhang D; Xu Y; Tang L
    Parasite Immunol; 2016 Oct; 38(10):635-41. PubMed ID: 27493141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.
    Lynch MM; Cernetich-Ott A; Weidanz WP; Burns JM
    Clin Vaccine Immunol; 2009 Mar; 16(3):293-302. PubMed ID: 19116303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single injection of 19 kda carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 (PyMSP1(19)) formulated with Montanide ISA and CpG ODN induces protective immune response in mice.
    Hirunpetcharat C; Mahakunkijcharoen Y; Jeamwattanalert P; Kittigul L; Mahannop P; Pichyangkul S
    Asian Pac J Allergy Immunol; 2011 Sep; 29(3):252-9. PubMed ID: 22053595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans.
    Wilson DW; Fowkes FJ; Gilson PR; Elliott SR; Tavul L; Michon P; Dabod E; Siba PM; Mueller I; Crabb BS; Beeson JG
    PLoS One; 2011; 6(11):e27705. PubMed ID: 22110733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.
    Alaro JR; Lynch MM; Burns JM
    Vaccine; 2010 Oct; 28(42):6876-84. PubMed ID: 20709001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection.
    Okafor CM; Anumudu CI; Omosun YO; Uthaipibull C; Ayede I; Awobode HO; Odaibo AB; Langhorne J; Holder AA; Nwuba RI; Troye-Blomberg M
    Malar J; 2009 Nov; 8():263. PubMed ID: 19930613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19).
    Ahlborg N; Ling IT; Holder AA; Riley EM
    Infect Immun; 2000 Apr; 68(4):2102-9. PubMed ID: 10722607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.